Skip to contentS
Sunshine Biopharma Inc.
S
SBFMSunshine Biopharma Inc. Q1 2026 · 10-Q
Revenue$8.09M$8.09M−9.1% vs Q1 2025 Net Income-$1.24M-$1.24MN/M vs Q1 2025 EPS, diluted—
Gross Profit$2,180,990−20.1% Operating Income-$1,395,597N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sunshine Biopharma Inc. · CIK 1402328 · Engraved from SEC EDGAR
Operating Cash Flow-$2,072,100N/M Free Cash Flowderived-$2,077,229N/M Margins · derivedGross margin27.0%−3.7 pt vs Q1 2025
Operating margin-17.3%−2.7 pt vs Q1 2025
Net margin-15.4%−2.1 pt vs Q1 2025
ended Mar 31, 2026 · filed May 13, 2026 · 43 d after period end